Ortho Clinical Diagnostics is a leading global provider of in-vitro diagnostics. We have an established track record for providing high-quality products and services to the global clinical laboratory and immunohaematology communities.
With over 100,00 Dialysis systems installed around the globe we are one of the world’s leading manufacturers of haemodialysis systems, our mission is to constantly improve the user friendliness, safety and efficiency of this complex technology. Our innovative and reliable technologies are designed to improve the clinical outcomes and safety of your patients.
Vifor Pharma is a world leader in iron preparations for the treatment of iron deficiency. The iron portfolio includes Ferinject®, an innovative intravenous iron replacement therapy, Venofer®, the leading intravenous iron product for the treatment of iron deficiency as well as the well-established oral iron, Maltofer®.
NxStage Medical, Inc. is a leading medical technology company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease (ESRD) and acute kidney failure. NxStage also has established a small number of dialysis clinics committed to the development of innovative care delivery models for patients with ESRD.
ANZSIN is a sub-group of the Australia and New Zealand Society of Nephrology. We are an Australia and New Zealand (ANZ) based special interest group in Interventional Nephrology. We encourage the setting of standards, training, experience/expertise along with safe and effective practice within Interventional Nephrology for Nephrologists primarily: addressing Renal Biopsy, Cuffed and non-Cuffed Catheter Insertion, Peritoneal Dialysis Catheter Insertion (nephrological), and Arterio-Venous Fistula formation (e.g. snuff box) and complication diagnosis and correction (e.g. Angioplasty and Stenting).
The Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) collects and reports the incidence, prevalence and outcome of dialysis treatment and kidney transplantation for patients with end stage kidney disease across Australia and New Zealand. The Registry was established in 1977 from the merger of separate dialysis and transplant registries to provide information on the patterns and outcomes of dialysis and kidney transplantation, and to support safety and quality activities and the planning of appropriate health services.
Cochrane Kidney and Transplant (previously known as the Cochrane Renal Group) was initially established on 1st March 1997 with its editorial base in Lyon in France. In May 2000, the editorial base moved to Sydney, Australia and in 2010 we celebrated the 10th anniversary of Cochrane Kidney and Transplant in Sydney.
We are one of 53 Cochrane Review Groups that are part of Cochrane, an international, independent not-for-profit organisation dedicated to providing up-to-date, accurate information about the effects of health care. Cochrane produces and disseminates systematic reviews of research on healthcare interventions. Its major product is the Cochrane Library.
The aim of Kidney Health Australia – Caring for Australasians with Renal Impairment (KHA-CARI) is to improve the health care and outcomes of paediatric and adult patients with kidney disease by helping clinicians and health care workers to adhere to evidence-based clinical practice as often as possible.
Kidney Health Australia is the national peak body for kidney disease, and promotes good kidney health though education, advocacy, research and support. A not-for-profit organisation dedicated to helping people with kidney disease, to improve their health outcomes and quality of life, and that of their families and carers.
Dialysis Australia is a respected and experienced provider of home-based dialysis services. As an enabler of in-home dialysis care, Dialysis Australia is changing the landscape for people living with Chronic Kidney Disease by allowing a greater number of patients to dialyse in the comfort of their own home.
PKD is the most common genetic disorder of the kidneys. Worldwide figures estimate up to 60,000 Australians are likely to be affected by PKD in their life. PKD Australia fund medical research to find a cure for PKD and connect, support and educate Australians and their families affected by PKD.